TrialLeukemia & lymphoma2013

Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

Clive S Zent et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.